MedTech News
GE HeatlhCare launches new advanced digital X-ray system
GE HealthCare (Nasdaq: GEHC)+
today announced the commercial launch of its advanced floor-mounted digital X-ray system.
Tumor-targeting fluorescent bacteria illuminate cancer for precision surgery
Accurate removal of tumors is the most critical aspect of cancer surgery, yet it remains a significant challenge in clinical practice. In breast cancer, for example, the positive margin rate—where cancer cells remain at the surgical boundary—can reach up to 35%, often requiring reoperation and increasing the risk of recurrence.
Paper-based device detects immune defects in 10 minutes with high accuracy
A 3D paper-based analytical device (3D-osPAD) with in situ gold signal amplification enables one-step, highly sensitive detection of anti-IFN-γ autoantibodies within 10 minutes, showing 10-fold improved sensitivity and high clinical accuracy for adult-onset immunodeficiency.
Predicting kidney disease trajectories with a simple blood test
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited condition that can lead to kidney failure. Being able to accurately predict how the disease will progress is very important for selecting the right treatments and providing effective patient counseling.
Researchers engineer rare immune cells to create powerful new cancer vaccine
In a new study published in Cancer Immunology Research, scientists at the Icahn School of Medicine at Mount Sinai have developed a novel method to generate billions of rare immune cells known as conventional type I dendritic cells (cDC1s), potentially paving the way for a new class of off-the-shelf cellular cancer vaccines.
Spirair wins FDA nod for bioresorbable sinus surgery implant
Spirair announced today that the FDA granted 510(k) clearance for its TurbAlign bioabsorbable implant device.
Boston Scientific Watchman wins FDA expansion for post-ablation patients
Boston Scientific (NYSE: BSX)+
has received expanded FDA approval for the use of its Watchman FLX and Watchman FLX Pro devices.
Johnson & Johnson’s TAR-200 for Bladder Cancer Granted FDA Priority Review
NDA for TAR-200 targets high-risk non-muscle invasive bladder cancer, highlighting potential to transform treatment for patients unresponsive to BCG therapy